英科医疗(300677) - 2024 Q1 - 季度财报

Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,119[24] - Liu Fangyi, a domestic natural person, holds 35.76% of the shares, totaling 231,664,007 shares[24] - The chairman and controlling shareholder, Liu Fangyi, increased his holdings by 321,400 shares, with a total investment of 6,751,992.00 RMB, demonstrating confidence in the company's future[47] Share Repurchase and Capital Structure - The company completed the repurchase and cancellation of 8,116,107 shares on March 5, 2024, accounting for 1.2372% of the total shares before the cancellation[29] - After the cancellation, the total share capital of the company changed from 656,009,601 shares to 647,893,494 shares[29] - The conversion price of "Yingke Convertible Bonds" was adjusted from 3.87 yuan per share to 3.64 yuan per share, effective from March 6, 2024[29] Financial Performance - Total assets increased to 29.45 billion CNY from 27.08 billion CNY, reflecting a growth of 8.7%[32] - Current assets rose to 17.93 billion CNY from 15.60 billion CNY, a 14.9% increase[32] - Non-current assets slightly increased to 11.52 billion CNY from 11.48 billion CNY[32] - Net profit for the quarter was 240.57 million CNY, compared to a net loss of 146.77 million CNY in the previous period[36] - Operating profit stood at 293.16 million CNY, a significant improvement from an operating loss of 150.10 million CNY[36] - Basic earnings per share improved to 0.36 CNY from a loss of 0.23 CNY[36] - Comprehensive income totaled 243.94 million CNY, compared to a comprehensive loss of 152.09 million CNY[36] Expenses and Income - Sales expenses increased to 67.90 million CNY from 50.85 million CNY, up 33.5%[36] - R&D expenses rose to 84.58 million CNY from 63.88 million CNY, a 32.4% increase[36] - Interest income surged to 99.40 million CNY from 68.91 million CNY, a 44.2% growth[36] Cash Flow and Liquidity - Sales revenue from goods and services received in cash increased to 1,962,563,806.00, up from 1,383,659,242.00 in the previous period, reflecting a significant growth in sales[38] - Net cash flow from operating activities improved to 161,970,968.00, compared to a negative cash flow of -174,585,120.00 in the previous period, indicating better operational efficiency[38] - Net cash flow from investing activities turned positive at 682,927,808.00, a significant recovery from -193,950,989.00 in the previous period, showing effective investment management[38] - Cash and cash equivalents increased to 10,058,833,363.00 from 7,221,706,750.00, indicating strong liquidity and financial health[48] Accounts Receivable and Inventory - Accounts receivable rose to 1,160,525,459.00 from 922,472,987.00, suggesting an increase in sales on credit[48] - Inventory levels increased to 1,310,099,106.00 from 1,149,999,485.00, possibly indicating higher production or slower sales[48] Investment Plans - The company plans to invest 20 million RMB as a limited partner in the Haining Qingling Venture Capital Fund, targeting a total fund size of up to 100 million RMB[46]